Geron Receives Milestone Payment from Merck Triggered by IND Filing for Telomerase Cancer Vaccine Candidate (wallstreet:online AG)
Geron Corporation (6345;Nasdaq:GERN) announced today that Merck & Co, Inc. has filed an Investigational

VIVUS Initiates Third Qnexa Phase 3 Trial in Obese Patients (FinanzNachrichten)
VIVUS, ( Nachrichten ) Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has initiated the third phase 3 study of Qnexa in obese patients with co-morbidities.